Tercica news from FierceBiotech
News
Ipsen inks a string of deals in expansion effort
France's Ipsen is buying out Tercica in a $404 million deal, one of three new pacts designed to Read more...
C&L: Lundbeck CEO resigns early
Denmark's H Lundbeck announced that its president and chief executive Claus Braestrup has resigned earlier than expected. Critical Therapeutics announced that Frank Thomas will resign as president Read more...
FDA approves Tercica's growth disorder drug
The FDA has approved Tercica's Somatuline Autogel, an injectable treatment for adult patients with acromegaly. Acromegaly is a rare disorder caused by too much growth hormone, resulting in enlarged Read more...
ALSO NOTED: Pharmaxis touts late-stage study; ALS gains orphan drug status; H5N1 passed human-to-human; and much more...
> Pharmaxis says that a late-stage study of its experimental drug for a chronic lung condition demonstrated its effectiveness. Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets